SpiderRock Advisors LLC Increases Stake in Moderna, Inc. (NASDAQ:MRNA)

SpiderRock Advisors LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 1,442.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 26,917 shares of the company’s stock after purchasing an additional 25,172 shares during the quarter. SpiderRock Advisors LLC’s holdings in Moderna were worth $1,799,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares in the last quarter. Capital World Investors grew its position in Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after acquiring an additional 29,566 shares in the last quarter. ARK Investment Management LLC grew its position in Moderna by 10.4% in the third quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after acquiring an additional 109,852 shares in the last quarter. Finally, National Pension Service grew its position in Moderna by 10.3% in the third quarter. National Pension Service now owns 813,893 shares of the company’s stock valued at $54,392,000 after acquiring an additional 75,817 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,184 shares of company stock valued at $238,531. 15.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRNA. Leerink Partners lowered their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research report on Tuesday, September 17th. TD Cowen lowered their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. UBS Group lowered their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Finally, Piper Sandler decreased their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $93.18.

Moderna Price Performance

NASDAQ:MRNA opened at $46.83 on Friday. The business’s 50-day moving average price is $61.85 and its 200 day moving average price is $99.16. The firm has a market cap of $18.00 billion, a P/E ratio of -3.04 and a beta of 1.69. Moderna, Inc. has a 52-week low of $46.57 and a 52-week high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) EPS. As a group, sell-side analysts predict that Moderna, Inc. will post -9.89 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.